GPR37 and central nervous system cancer: Knockdown of GPR37 leads to p-Akt reduction, G1 phase arrest, and upregulation of the cyclin-dependent kinase inhibitor p21, linking GPR37 to oncogenic signaling and cell cycle progression in glioma cells (Bian et al., 2024).